A global biotech is axing more of its Greater Washington workforce, eliminating nearly 100 positions across multiple waves of ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

BioNTech and Pfizer's COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech's Chief Executive told Reuters, as the firm ...

Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.

In November, American pharmaceutical giant Pfizer and its German partner BioNTech began enrolling child volunteers aged 12 to 17 in the Phase 2/3 trials of their two-dose COVID-19 vaccine. Now ...

BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur ...

BioNTech stock, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained ...

Türeci co-founded BioNTech, a German company that partnered with pharmaceutical giant Pfizer to develop the first U.S.-authorized COVID-19 vaccine.

BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...

Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October or early November, BioNTech CEO and co-founder Ugur ...